Alpha 2.0
Login Register
» Authors » Gertjan Wolbink

Gertjan Wolbink

Explore the profile of Gertjan Wolbink including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 82
Citations 1851
Followers 0
Related Specialties
Rheumatology
Pharmacology
Allergy & Immunology
Top 10 Co-Authors
Theo Rispens
Laura Boekel
Michael T Nurmohamed
Femke Hooijberg
Sander W Tas
Taco W Kuijpers
Maurice Steenhuis
Luuk Wieske
Filip Eftimov
S Marieke van Ham
Published In
Ann Rheum Dis
Lancet Rheumatol
RMD Open
J Rheumatol
Clin Exp Rheumatol
Affiliations
Soon will be listed here.
Recent Articles
1.
Reference intervals of work ability and productivity loss and their use in patients with inflammatory rheumatic and musculoskeletal diseases
Capelusnik D, Smeets W, Webers C, Ramiro S, Nikiphorou E, Braekers R, et al.
RMD Open . 2025 Jan; 11(1. PMID: 39762121
Objectives: To establish reference intervals (RIs) for work ability, at-work productivity loss and overall productivity loss in the general working population and to compare work ability and at-work productivity loss...
2.
Precision Dosing of Intravenous Tocilizumab: Development of Pharmacokinetic Model-Derived Tapering Strategies for Patients With Rheumatoid Arthritis
Hooijberg F, van den Berg S, Layegh Z, Leeuw M, Elkayam O, de Vries A, et al.
Ther Drug Monit . 2024 Nov; PMID: 39509293
Background: Tocilizumab targets the interleukin-6 receptor, and dosing is complex owing to its nonlinear clearance related to target binding. Therefore, tapering tocilizumab requires a different approach than that of tumor...
3.
Methotrexate treatment hampers induction of vaccine-specific CD4 T cell responses in patients with IMID
Kummer L, Blanco L, Kreher C, Bos A, Kuijper L, Verstegen N, et al.
RMD Open . 2024 Oct; 10(4). PMID: 39375177
Objectives: Methotrexate (MTX) is one of the most commonly used medications to treat rheumatoid arthritis (RA). However, the effect of MTX treatment on cellular immune responses remains incompletely understood. This...
4.
Next-generation rheumatoid factor assay provides improved predictive power for the development of arthritis in patients at risk
Oskam N, Ooijevaar-De Heer P, Kos D, van Boheemen L, van Schaardenburg D, Wolbink G, et al.
RMD Open . 2024 Aug; 10(3). PMID: 39164049
Objective: Rheumatoid arthritis (RA) is characterised by the presence of autoantibodies, among which those targeting the constant region of immunoglobulin G (IgG), called rheumatoid factors (RF). Despite this link, RFs...
5.
Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomised controlled trial
Lend K, Lampa J, Padyukov L, Hetland M, Heiberg M, Nordstrom D, et al.
Ann Rheum Dis . 2024 Jul; 83(12):1657-1665. PMID: 39079894
Objectives: To investigate whether rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPAs) and shared epitope (SE) allele-related genetic markers associate with treatment response to abatacept, certolizumab pegol or tocilizumab versus active...
6.
Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Alsoud D, Moes D, Wang Z, Soenen R, Layegh Z, Barclay M, et al.
Ther Drug Monit . 2024 Apr; 46(3):291-308. PMID: 38648666
Background: Infliximab, an anti-tumor necrosis factor monoclonal antibody, has revolutionized the pharmacological management of immune-mediated inflammatory diseases (IMIDs). This position statement critically reviews and examines existing data on therapeutic drug...
7.
Patient-perspective and feasibility of home finger-prick testing to complement and facilitate large-scale research in rheumatology
Besten Y, Boekel L, Steenhuis M, Hooijberg F, Atiqi S, Leeuw M, et al.
RMD Open . 2024 Apr; 10(2). PMID: 38642927
Background: During the COVID-19 pandemic, we developed a digital research platform to longitudinally investigate COVID-19-related outcomes in patients with rheumatic diseases and healthy controls. We used home finger-prick testing in...
8.
Population Pharmacokinetics of Adalimumab in Juvenile Idiopathic Arthritis Patients: A Retrospective Cohort Study Using Clinical Care Data
Nassar-Sheikh Rashid A, Hooijberg F, Bergkamp S, Gruppen M, Kuijpers T, Nurmohamed M, et al.
Paediatr Drugs . 2024 Apr; 26(4):441-450. PMID: 38630199
Background And Objective: Juvenile idiopathic arthritis (JIA) is a chronic autoimmune disorder that primarily affects the joints in children. Notably, it is known to co-occur with uveitis. Adalimumab, a monoclonal...
9.
Work participation and the COVID-19 pandemic: an observational study in people with inflammatory rheumatic diseases and population controls
Butink M, Boekel L, Boonen A, deRijk A, Wolbink G, Webers C
Rheumatol Adv Pract . 2024 Apr; 8(2):rkae026. PMID: 38566834
Objective: During the coronavirus disease 2019 (COVID-19) crisis, people with inflammatory rheumatic diseases (iRDs) might have been more vulnerable for adverse work outcomes (AWOs) and restrictions in work ability and...
10.
T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination
Verstegen N, Hagen R, Kreher C, Kuijper L, van den Dijssel J, Ashhurst T, et al.
J Neurol Neurosurg Psychiatry . 2024 Mar; 95(9):855-864. PMID: 38548324
Background: Messenger RNA (mRNA) vaccines provide robust protection against SARS-CoV-2 in healthy individuals. However, immunity after vaccination of patients with multiple sclerosis (MS) treated with ocrelizumab (OCR), a B cell-depleting...